Connect with us

Biotech

Moderna Continues to Strengthen its Presence in Spain

In ten years since its inception, Moderna has transformed from a research-stage company advancing programs in the messenger RNA (mRNA) field to a company with a diverse clinical portfolio of vaccines and treatments in six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation.

Published

on

Moderna continues to strengthen its team in Spain. Following the appointments of Marisol Gimeno and Maite Mateo, the Spanish subsidiary of the US biotech company has added Johana Rodriguez to its staff as a new medical advisor for Spain and Portugal, according to sources at the company.

The position of medical advisor is that of a professional who acts as a link between the market and the research area and collaborates closely with the marketing and sales department, designing the scientific content of the assigned products and providing support to the person responsible for the product. He also collaborates in international and local clinical trials.

Rodriguez joins Moderna from Amryt Pharma, a pharmaceutical company specialized in rare and orphan diseases, where he has worked for more than three years as medical advisor for Spain, Portugal, and Greece. Moderna’s recent incorporation has a Master’s degree in Humanitarian Medicine from the Complutense University of Madrid and a Master’s degree in Public Health from the Rey Juan Carlos University.

Read more about Moderna and find other financial news with our companion app Born2Invest.

Moderna strengthens its team in Spain after appointments such as Marisol Gimeno and Maite Mateo

Before joining Amryt Pharma, Rodríguez worked for companies such as Praxis Pharmaceutical and Astellas Pharma as medical advisor and project manager in the area of anti-infectives, respectively.

Rodriguez also served as medical science liaison (MSL) at Esteve and Gilead. Currently, the MSL is a person with a technical profile (generally with a medical degree or PhD), specialized in a specific therapeutic area and in charge of interacting with the medical opinion leaders in his or her sector, better known as Key Opinion Leaders or KOLs.

SEE ALSO  Why Australia’s Baby Boomers keep their homes amid expensive property market

In ten years since its inception, Moderna has transformed from a research-stage company advancing programs in the messenger RNA (mRNA) field to a company with a diverse clinical portfolio of vaccines and treatments in six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing facility that enables clinical and commercial production at scale.

The company expects to close 2022 manufacturing 500 million doses of its Covid-19 vaccine in Spain

The company closed 2021 with a profit of $12.2 billion, compared with a loss of $747 million recorded in 2020. Moderna’s total revenues in 2021 were $18.471 billion, compared with $803 million in 2020. Of this total amount, product sales were $17.675 million, while in 2020 they were $200 million 2020.

In Spain, the biotech company expects to end 2022 by manufacturing 500 million doses of its anti-Covid-19 vaccine, the result of its agreement with Laboratorios Farmacéuticos Rovi. So far, the company has manufactured just over 350 million doses, which it has distributed to more than sixty countries. On a global scale, these 500 million translate into more than 800 million doses.

In Spain, these plans are forged with the renewal of the agreement between Moderna and Rovi for ten more years to increase the formulation, aseptic filling, inspection, labeling, and packaging capacities in Rovi’s facilities in Madrid, San Sebastián de los Reyes, and Alcalá de Henares.

__

(Featured image by ncb80 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.